Lapatinib (tosylate)

Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

Product Specifications

CAS Number

[1187538-35-7]

Product Name Alternative

GW572016 (tosylate) ; GW2016 (tosylate)

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Autophagy; EGFR; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lapatinib-tosylate.html

Solubility

10 mM in DMSO

Smiles

O=S(C1=CC=C(C)C=C1)(O)=O.O=S(CCNCC2=CC=C(C3=CC=C4C(C(NC5=CC(Cl)=C(C=C5)OCC6=CC(F)=CC=C6)=NC=N4)=C3)O2)(C)=O

Molecular Formula

C36H34ClFN4O7S2

Molecular Weight

753.26

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1 (2) :85-94